. | Diagnosis . | 2 mo . | 3 mo . | 4 mo . |
|---|---|---|---|---|
| Serum M-spike* | 0.2 | 0.1 | 0.07 | < 0.05† |
| Urine M-spike* | 0.5 | — | 0 | 0† |
| Plasma cells, % BM | 5 | — | — | < 5 |
| Free lambda | 395 | 91 | 50 | 31 |
| B2M, mg/L | 7.6 | 2.8 | 2.2 | 1.7 |
| Serum IL-6‡ | 43 | < 5 | — | — |
| Serum VEGF§ | 2398 | 2510 | < 31 | 33 |
. | Diagnosis . | 2 mo . | 3 mo . | 4 mo . |
|---|---|---|---|---|
| Serum M-spike* | 0.2 | 0.1 | 0.07 | < 0.05† |
| Urine M-spike* | 0.5 | — | 0 | 0† |
| Plasma cells, % BM | 5 | — | — | < 5 |
| Free lambda | 395 | 91 | 50 | 31 |
| B2M, mg/L | 7.6 | 2.8 | 2.2 | 1.7 |
| Serum IL-6‡ | 43 | < 5 | — | — |
| Serum VEGF§ | 2398 | 2510 | < 31 | 33 |
Therapy started at diagnosis with melphalan (10 mg/m2 intravenously every 28 days for 3 months) and dexamethasone (20 mg orally daily for 4 days every 15 days for 2 months, then monthly afterward); bevacizumab (5 mg/kg intravenously over 90 minutes) was given on months 2 and 3.
BM indicates bone marrow; B2M, β2-microglobulin; and IL-6, interleukin-6.
Immunofixation was positive for free lambda
Near complete remission (positive immune fixation)
Normal range, < 5 pg/mL
Normal range, 38-86 pg/mL